MCM
DWTX

Masters Capital Management’s Dogwood Therapeutics DWTX Stock Holding History

Masters Capital Management’s Portfolio DWTX Stock Details DWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-26,000
Closed -$2.75M – 59
2022
Q2 		$2.75M Hold
26,000
– – 0.13% 50
2022
Q1 		$2.91M Hold
26,000
– – 0.12% 57
2021
Q4 		$3.33M Hold
26,000
– – 0.14% 60
2021
Q3 		$3.44M Buy
26,000
+2,000
+8% +$277K 0.14% 66
2021
Q2 		$3.77M Hold
24,000
– – 0.11% 62
2021
Q1 		$3.44M Buy
24,000
+6,082
+34% +$1.06M 0.11% 55
2020
Q4 		$3.36M Buy
+17,918
New +$4.32M 0.2% 54

Other funds holding DWTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
CA
Cetera Advisors Denver, Colorado $12.7B AUM 22.7% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Masters Capital Management's DWTX Position: Q3 2022 in Review

Masters Capital Management sold out of Dogwood Therapeutics (DWTX) in Q3 2022, closing a stake of 26,000 shares — an estimated $2.75M sold.

Masters Capital Management first reported a position in DWTX in Q4 2020 and held it in 7 quarters. The position peaked at $3.77M in Q2 2021. 25 funds tracked by Wall St. Rank hold DWTX as of Q3 2022.

  • Masters Capital Management reported no remaining Dogwood Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Masters Capital Management sold 26,000 Dogwood Therapeutics shares in Q3 2022, an estimated $2.75M.
  • Masters Capital Management first reported a position in Dogwood Therapeutics in Q4 2020 and held it in 7 quarters.
  • Masters Capital Management's Dogwood Therapeutics position peaked at $3.77M in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Dogwood Therapeutics as of Q3 2022.

Based on Masters Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.